Scarica l'app Stockscreener
3.48
4.66%
-0.17
Pre-mercato:
3.42
-0.06
-1.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.65
Aprire:
$3.6
Volume 24 ore:
1.11M
Relative Volume:
0.49
Capitalizzazione di mercato:
$382.02M
Reddito:
-
Utile/perdita netta:
$-209.38M
Rapporto P/E:
-1.8542
EPS:
-1.8768
Flusso di cassa netto:
$-179.81M
1 W Prestazione:
+4.19%
1M Prestazione:
+1.46%
6M Prestazione:
-7.94%
1 anno Prestazione:
-7.20%
Intervallo 1D:
$3.43
$3.659
Intervallo di 1 settimana:
$3.27
$3.66
Portata 52W:
$2.53
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.48 | 400.68M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-08-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-30 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Downgrade | Needham | Buy → Hold |
| 2025-05-27 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-30 | Iniziato | Wedbush | Outperform |
| 2024-12-18 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares - Investing.com
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock - Investing.com
Rocket (RCKT) EPS and Revenue: EPS Falls Short of Its Estimate on the Day; After Results: Shares Finish 1.76% Down in the Latest SessionEarnings Outlook Update - Vinanet
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill - Stock Titan
Rocket Pharma (NASDAQ: RCKT) officer to resell $2.1K in vested shares - Stock Titan
Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares - Stock Titan
Rocket Pharmaceuticals general counsel Wilson sells $11,809 in stock - Investing.com
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock - Investing.com
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals general counsel Wilson sells $11,809 in stock By Investing.com - Investing.com Canada
RCKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Rocket Pharmaceuticals' General Counsel Martin Wilson Sells Shares to Cover RSU Tax Obligations - Kalkine Media
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock - MarketBeat
Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Don't Ignore The Insider Selling In Rocket Pharmaceuticals - simplywall.st
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals Executive Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock - MarketBeat
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock - MarketBeat
Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding - Stock Titan
RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares - Stock Titan
Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals - Stock Titan
Rocket Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5 - Moomoo
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026) - Stock Titan
TD Cowen Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus - Yahoo Finance
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside - TradingView
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15 - GuruFocus
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a shareEarnings Preview - TradingView
ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12 - Bitget
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - AOL.com
ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings - Quiver Quantitative
Rocket Pharmaceuticals: Q2 Earnings Snapshot - barchart.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
Rocket Pharmaceuticals Q2 adj EPS $(0.37) misses $0.24 estimate - scanx.trade
BRIEF-Rocket Pharmaceuticals Q2 EPS USD 1.08 - Bitget
Rocket Pharmaceuticals reports Q2 2026 net income $123.2M, cash $283.7M, eyes Danon pivotal progress - tradingview.com
Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 6c; offers guidance - streetinsider.com
ROCKET PHARMACEUTICALS, INC. Q2 2026: Revenue $0 Net income $123.2M, EPS $1.08— 10-Q Summary - tradingview.com
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale - TradingView
Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):